C-AMBDSMSbiotech
Small Mobile Stem cells, allogeneic cell therapy, regenerative medicine
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-AMBD
C-AMBDC-AMBDSmall Mobile Stem cells, allogeneic cell therapy, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells). The primary objective of this study is to determine the safety of SORT-COPD (SMS cells) at three doses in people with chronic obstructive pulmonary disease.
SMSbiotech Interviews with Dr. Roger Schechter EPISODE 1: Aging and Cell Therapy | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We& … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Scientific Publications | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiring! We’re always looking for talented people.
BioNeex Interview with SMSbiotech | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiring! We’re always looking for talent … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Reversing lysosomal dysfunction restores youthful state in aged hematopoietic stem cells | Saghi Ghaffari | 20 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
RNIB - Health and Wellbeing / Novel Research Could Help Reverse Damage Caused By COPD {"webUser":null} Menu Podcasts Advertisers Creators Help & support Sign up Sign in {"flashNotices":[]} Podcasts Advertisers Creators Help & support Search podcasts Sign up Sign in RNIB - Health and Wellbeing Novel Research Could Help Reverse Damage Caused By COPD Season 2 Episode 1059 · Mar 31, 2025, 12:30 PM - -- - -- 1× Headliner Embed Embed code See more options Share Facebook X Subscribe A San Diego-based regenerative medicine company is pioneering a novel approach to treating Chronic
SMSbiotech Blog | Science News, Insights & Presentations Wait, before you go! Subscribe to get important updates and helpful insights delivered straight to your inbox. Thank you! We received your submission! Oops! Something went wrong Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission
New Facility Opens In San Marcos, CA | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiring! We’re always looking for tal … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
SMSbiotech Welcomes New Board of Advisor Member Dr. Jason P. Kirkness | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hir … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
SMSbiotech Receives Green Light for Phase I Clinical Trial in Australia, Targeting COPD | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Care … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
SMSbiotech Founder Featured on “HealthTech CEO Wisdom” Podcast | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiring! We … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
SMSbiotech Announces Collaboration with Acculab Life Sciences | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiring! We’ … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Getty Images Oleh_Slobodeniuk 873509294 User validation
An interview with Andulkader Rahmo, CEO of SMS Biotech Blog An interview with Andulkader Rahmo, CEO of SMS Biotech As a premier life sciences incubator and consultancy, IntuitiveX is always in search of founders and entrepreneurs who push the boundaries of what is possible within medical research and technology. In this interview, IntuitiveX shares the story of a life science entrepreneur who — in response to COVID-19 — is pivoting his company to provide a cell therapeutic approach that regenerates the human lung tissue of people affected by COVID-19. Introducing Andulkader Rahmo Andulkader Ra
HTB Forums 2023: Creating IP awareness in SMEs with case studies – Build to sell & IP strategy and management - IP Business Academy Your global IP-Management Education Platform Your global IP-Management Education Platform Search for: × Home Education Academic IP Management Training at CEIPI IP Management Education CEIPI Certificates CEIPI University Diploma (DU IPBA) CEIPI Master (MIPLM) University Industry Case Studies MIPLM Dinner Speeches PhD/Master/Research Corporate University Graduate School Research Areas Excellence Groups Mentors Application Fellowship program Prof. Norbert … e Groups Mentors Application Fellowship program Prof. Norbert Haugg Sponsorship Award Lecturers | Experts | Content Creators Open Foresight Program Program Overview Benefits of the Program Open Foresight Board Join the Board Career Community Community support of the CEIPI IP Business Academy Content creator support of the CEIPI IP Business Academy Participants Community IP Subject Matter Expert Ambassador Partners Cases | Examples | Industry Partners About Share on Facebook P … gement Days CEIPI Summer School MIPLM Dinner Speech MIPLM Industry Case Studies Fellowship Program Job Posting Research Project DIN77006 Eco Systems GreenTech Industrial IoT MedTech & Digital Health Systems Quantum Technology Robotics & Autonomous Systems Smart Advertising & Media Smart City Smart Construction Smart Farming Smart Grid Smart Home Smart Mobility Unified Patent Court UPC Institutions DPMA European Commission European Patent Office European Union Inte … Kolloquium des Graduiertenkollegs Rat für Formgebung – German Innovation Award Weickmann Munich Experience Exchange Press / Interviews Publication Column Deep dive Seminar / Workshop Forum Seminare Training Webinar Surveys Tags 5G Agile App protection Artificial Intelligence awareness Big Data Blockchain Brand Management Business Development Business Model Career China Compliance Counterfeiting Customer Journey Design Thinking Digital Business Model Digital Patent Digi
SMSbiotech Interviews with Dr. Roger Schechter EPISODE 3: Angiogenesis and SMS Cells | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Rion | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Rion RION is a clinical-stage regenerative medicine company based in Rochester, MN, dedicated to revolutionizing exosome science to heal from within. Founded in 2017 out of the Mayo Clinic Employee Entrepreneurial Program, the company focuses on harnessing the power of platelet-derived exosomes, particularly through their proprietary Purified Exosome Product (PEP™), to promote tissue regeneration and advance regenerative medicine. RION aims to change the approach to regen
Facebook Logged in on your phone? Scan with your phone's camera and confirm the codes match. IVP-UXQ-PNWO Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Thanks to JP Morgan organizers for inviting us to the conference. | Abdulkader Rahmo LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s U
SMSbiotech Engages Exemplar Capital for Strategic Investment Banking Services Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Mul … n research and development. One use of investment capital raised would be application to the FDA for 510(k) clearance and commercialization of human ECM's as a medical device to treat wounds. Richard Borror , Chairman of SMS, commented, "We are impressed by the expertise, commitment and experience of Exemplar Capital professionals in the biotech and medical device arena. We are indeed happy to cement a long-term investment banking relationship with the firm." Said Chris … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
SMSbiotech Engages Exemplar Capital for Strategic Investment Banking Services | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We … use in research and development. One use of investment capital raised would be application to the FDA for 510(k) clearance and commercialization of human ECM’s as a medical device to treat wounds. Richard Borror, Chairman of SMS, commented, “We are impressed by the expertise, commitment and experience of Exemplar Capital professionals in the biotech and medical device arena. We are indeed happy to cement a long-term investment banking relationship with the firm.” Said Christ … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
SMSbiotech Secures New Japanese Patent | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiring! We’re always looking for t … milestone underscores SMSbiotech’s continued progress toward democratizing the application of adult stem cell technologies for human health. Resources No items found. Published on: 26 Oct 2025 Copy link This is some text inside of a div block. Back to Lobby SMSbiotech Attends the 44th Annual J.P. Morgan Healthcare Conference Next Article SMSbiotech Presents Investigational SMS Cell Platform at International Orthopedics Webinar Next Article SMSbiotech Appoints Michael C. Swar … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Gamma Biosciences | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Gamma Biosciences Gamma Biosciences is a unique investment platform focused on supporting small to mid-size companies involved in the development and production of biopharmaceuticals. They back innovators developing tools to support the next generation of biologic medicine, working closely with management teams to identify high-impact value drivers and providing capital and expertise to support their achievement. The company leverages extensive industry exper … mmercialization and productization support Assistance with product development, application testing, regulatory certification planning and market launch for bioprocessing tools and consumables. Strategic technical collaborations and co-development Partnerships to adapt reagents and consumables for integration with automated manufacturing platforms and to co-develop clinical-grade reagents and analytics. Expertise Areas Advanced bioprocessing and biomanufacturing Bioseparation … s Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology A licensing agreement to expand ligand discovery and development capabilities. Gamma Biosciences Acquires Nanopareil to Advance Next-Generation Purification Capabilities of Astrea Bioseparations Acquisition of Nanopareil to enhance downstream purification technologies. Launch of Univercells Technologies for Intensified, Automated Technologies Unive … s Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology Licensing agreement for affinity ligand technology. Gamma Biosciences Acquires Nanopareil to Advance Next-Generation Purification Capabilities of Astrea Bioseparations Acquisition of Nanopareil. Launch of Univercells Technologies for Intensified, Automated Technologies Launch of new bioprocessing platform. Gamma Biosciences Acquires Univercells Tec
Joe Kiani’s Patient Safety Foundation Holds 12th Annual Summit - Orange County Business Journal Lists & Leader Boards OCBJ Weekly Lists Leader Board 2025 OC500 – Directory of Influence 2025 OC’s Wealthiest Purchase Book of Lists Behind the Scenes Civic Philanthropy Economy Media Awards-Honors Organizations People Government Education Finance/Services Finance Services Small Business Health Care Lifestyle Tourism Hotels Entertainment Sports Food Restaurants Food Reviews Manufacturing Automobiles Manufacturing Retail Apparel Transportation Defense Real Estate Real Estate The Luxury Gallery T
Healthcare Private Placement and M&A Transactions Review Week Ending October 19, 2025 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending Oc … ctober 15, 2025. Andera Partners, Frazier Healthcare Partners, Ascenta Capital, Fund+, EQT Life Sciences, Nextech Invest, Deep Track Capital, High-Tech Gründerfonds, Seventure Partners, Bayern Kapital, OCCIDENT and Wellington Management also participated in the round. The company is a developer of chemotherapeutic drugs designed to fight cancer and chronic diseases. Kardigan: The company raised $254 million of Series B venture funding from Sequoia Heritage, ARCH Venture Partn … e company received $250 million of development capital from Thiel Bio, Founders Fund and other investors on October 16, 2025. The company is a developer of robotically-assisted ultrasound technology for non-invasive tissue ablation and tumor destruction. VeraDermics: The company raised $150 million of Series C venture funding in a deal led by SR One Capital Management on October 16, 2025, putting the company’s pre-money valuation at $140 million. LifeSci Venture Partner … rma, Pontifax Venture Capital, Pureos Bioventures, RA Capital Management, aMoon Fund and Surveyor Capital also participated in the round. The company is a developer of an antibody-drug conjugate platform designed to address resistance and improve safety in cancer therapy through novel payload innovation. Pelage: The company raised $120 million of Series B venture funding in a deal led by GV and ARCH Venture Partners on October 15, 2025, putting the company’s pre-money v … ;s pre-money valuation at $203 million. Main Street Advisors, Visionary Venture Fund and YK Bioventures also participated in the round. The company is a developer of small molecule therapeutics targeting hair follicle stem cell metabolism for treating androgenetic alopecia and hair loss. Peptilogics: The company raised $78 million of Series B ven
📍 Conference Announcement We’re heading to Advanced Therapies Week 2026 in San Diego! From February 9–12, the SMSbiotech leadership and scientific team will be onsite at the San Diego Convention Centre, connecting with industry leaders across cell therapy, regenerative medicine, and advanced biomanufacturing. 🎤 Spotlight Session Dr. Abdulkader Rahmo, President & Chief Scientific Officer, will present: “Exploring Novel Cell Sources to Overcome Limitations in Current Modalities” 🗓 February 12 | ⏰ 11:45 AM – 12:00 PM Interested in meeting with our team? Reach out to schedule time in advanc
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Meet Abdulkader Rahmo, PhD. | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiring! We’re always looking for talented peo … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Scientist.com Innovation Hub | Trends & Innovations Across the Pipeline --> --> --> --> Skip to Main Content Clients Our Platform Manage life science work from request to results Vendor Network Guided Buying Workflow Automation Regulatory Compliance Actionable Insights Your Pipeline Unified platform designed to support the full lifecycle of drug development Discovery & Preclinical Clinical PharmDev & Manufacturing Medical & Commercial AI Capabilities The only AI orchestration engine built for life sciences Source, Manage, and Scale External Research Request a Demo Request a Dem … e (RWE) Safety & Pharmacovigilance Toxicology Medical Communications Cancel Apply Email address Subscribe I would like to receive the monthly Scientist.com newsletter. I agree to receive email communication from Scientist.com and accept the data privacy statement. By submitting your information, you agree to our Terms of Service and Privacy Policy . You can opt out anytime. Blog Accelerating the Design–Build–Test–Learn Cycle for AI-Driven Antibody Discovery Read blog … e (RWE) Safety & Pharmacovigilance Toxicology Medical Communications Cancel Apply Email address Subscribe I would like to receive the monthly Scientist.com newsletter. I agree to receive email communication from Scientist.com and accept the data privacy statement. By submitting your information, you agree to our Terms of Service and Privacy Policy . You can opt out anytime. © 2026 Scientist Cookies Policy Global Privacy Policy We use cookies for various purposes including
Company News | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiring! We’re always looking for talented people. Join our t … afayelyan, for an interview. May 8, 2020 Company News Insights SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment SMSbiotech, Inc. Proposal Outline to Biomedical Advanced Research and Development Authority March 16, 2020 Company News Other Indications Science SMSbiotech Completes Second Clinical Test for Chronic Non-Healing Wound Product SMSbiotech is pleased to announce the successful completion of the Skin Prick clinical test for its wound ... March 11, 2020 Comp
Joe Kiani Joins SMSbiotech as Chairman - Orange County Business Journal Lists & Leader Boards OCBJ Weekly Lists Leader Board 2025 OC500 – Directory of Influence 2025 OC’s Wealthiest Purchase Book of Lists Behind the Scenes Civic Philanthropy Economy Media Awards-Honors Organizations People Government Education Finance/Services Finance Services Small Business Health Care Lifestyle Tourism Hotels Entertainment Sports Food Restaurants Food Reviews Manufacturing Automobiles Manufacturing Retail Apparel Transportation Defense Real Estate Real Estate The Luxury Gallery Tech Tech Start-Ups Event
Scientist.com Innovation Hub | Trends & Innovations Across the Pipeline --> --> --> --> Skip to Main Content Clients Our Platform Manage life science work from request to results Vendor Network Guided Buying Workflow Automation Regulatory Compliance Actionable Insights Your Pipeline Unified platform designed to support the full lifecycle of drug development Discovery & Preclinical Clinical PharmDev & Manufacturing Medical & Commercial AI Capabilities The only AI orchestration engine built for life sciences Source, Manage, and Scale External Research Request a Demo Request a Dem … e (RWE) Safety & Pharmacovigilance Toxicology Medical Communications Cancel Apply Email address Subscribe I would like to receive the monthly Scientist.com newsletter. I agree to receive email communication from Scientist.com and accept the data privacy statement. By submitting your information, you agree to our Terms of Service and Privacy Policy . You can opt out anytime. Blog Accelerating the Design–Build–Test–Learn Cycle for AI-Driven Antibody Discovery Read blog … e (RWE) Safety & Pharmacovigilance Toxicology Medical Communications Cancel Apply Email address Subscribe I would like to receive the monthly Scientist.com newsletter. I agree to receive email communication from Scientist.com and accept the data privacy statement. By submitting your information, you agree to our Terms of Service and Privacy Policy . You can opt out anytime. © 2026 Scientist Cookies Policy Global Privacy Policy We use cookies for various purposes including
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
SMSbiotech Engages Exemplar Capital for Strategic Investment Banking Services - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country SMSbiotech Engages Exemplar Capital for Strategic Investment Banking Services October 1, 2020 | 2 min read Twitter LinkedIn Facebook Email Print SMSbiotech, a privately held biotech pioneer, has engaged the national investment banking firm, Exemplar Capital, for the purposes of strategic advisory services … n research and development. One use of investment capital raised would be application to the FDA for 510(k) clearance and commercialization of human ECM's as a medical device to treat wounds. Richard Borror , Chairman of SMS, commented, "We are impressed by the expertise, commitment and experience of Exemplar Capital professionals in the biotech and medical device arena. We are indeed happy to cement a long-term investment banking relationship with the firm." Said Chris … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
SMSbiotech Receives Green Light for Phase I Clinical Trial in Australia, Targeting COPD - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases SMSbiotech Receives Green Light for Phase I Clinical Trial in Australia, Targeting COPD March 18, 2025 | 2 min read Twitter LinkedIn Facebook Email Print SAN MARCOS, Calif.--(BUSINESS WIRE)--SMSbiotech has announced a significant milestone in its pursuit of its regenerative medicine technology, securing a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
SMSbiotech Initiates Groundbreaking Phase 1 Human Clinical Trial for COPD - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinio … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases SMSbiotech Initiates Groundbreaking Phase 1 Human Clinical Trial for COPD August 21, 2025 | 2 min read Twitter LinkedIn Facebook Email Print MELBOURNE, Australia--(BUSINESS WIRE)-- #biotech --SMSbiotech, a San Diego–based leader in regenerative medicine, today announced the initiation of its first-in-huma … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
SMSbiotech Establishes a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Chemical Defense - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases SMSbiotech Establishes a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Chemical Defense April 22, 2025 | 1 min read Twitter LinkedIn Facebook Email Print SAN MARCOS, Calif.--(BUSINESS WIRE)-- SMSbiotech, Inc. is pleased to announce the signing of a Coopera … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
Dr. Abdulkader Rahmo, SMSbiotech --> --> --> --> Featured by Newsweek & World Class Media Outlets Reports Events Interviews Careers About Search --> Home Interviews Dr.Abdulkader Rahmo Dr.Abdulkader Rahmo CEO SMSbiotech 26 January 2026 Share Interview SMSbiotech specializes in the development of small, mobile stem cells (SMS cells) with unique features such as rapid motility and resilience, offering potential therapeutic applications for tissue repair, inflammation control, and immune system modulation. SMS cell therapy was discovered and named by you. How does it differ from other stem cell t
3D Bioprinting: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent Valuation Analysis, Patentability, Freedom to Operate, Pockets of Innovation, Existing White Spaces, and Claim Analysis) Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST … g into consideration important parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (factoring in value associated with the gross domestic product (GDP) of a particular region). Patentability and Freedom to Operate A systematic approach to identify relevant areas of innovation by analyzing published IP documents (representative of unique patent families), by defining the uniqueness of patented / patent pending inno … e chapter highlights the advantages of 3D bioprinting, as well as discusses the application areas and future perspectives associated with this domain. Chapter 6 includes a review of the various patents and affiliated IP documents that have been published related to 3D bioprinting, since the year 2000. It also features an in-depth analysis of published IP documents, representing unique patent families across various global jurisdictions, and includes insightful inferences rela … s into consideration important parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (factoring in value associated with the gross domestic product (GDP) of a particular region). Chapter 9 provides a detailed summary of the patent applications (representative of unique patent families) that were filed across different jurisdictions and their relative value in the IP ecosystem. The analysis segregates the captured in … iew 5.2. 3D Printing Process 5.3. Key Historical Milestone 5.4. Advantages, Key Application Areas and Future Perspective of 3D Bioprinting 6. Overall Intellectual Property Landscape 6.1. Overview 6.2. Analysis of Simple Patent Families 6.3. Key Innovation Categories 6.4. Insights from Patent Applications 6.5. Insights from Granted Patents 7. Key
SMSbiotech Launches First-in-Human Trial of Small Mobile Stem Cells for COPD in Australia 27 June, 2026 | Saturday BioPharma America BioPharma Europe BioPharma Middle East BioPharma Africa BioPharma APAC Events Media Pack Login BioPharma Pharma & Biopharma Manufacturing Pharma Research Pharma QC Clinical Trials Drug Discovery Drug Approval BioSimilar Pharma Packaging LAB LAB Business LAB Health & Safety LAB Products LAB Design LAB Testing
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
SMSbiotech Appoints Michael C. Swartzburg as Chief Financial Officer | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers We're hiri … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
NellOne Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies NellOne Therapeutics NellOne is an early stage biopharmaceutical company pioneering advances in regenerative medicine. Its mission is to relieve suffering and restore lives by returning damaged soft and hard tissue to its pre-injury state, utilizing the NELL1 protein to promote tissue regeneration, control inflammation, and improve patient outcomes. The company is dedicated to harnessing the power of the NELL1 / NV1 protein to improve outcomes for patients … ate efficacy, optimize formulations, and support regulatory filings. Government grant-supported preclinical R&D Management and execution of SBIR-funded preclinical research programs, including evaluation in cultured human tissues and animal infection models to generate translational data for regulatory and development milestones. Expertise Areas Regenerative medicine and tissue engineering Recombinant protein therapeutic development Preclinical translational development f … timization for biologics Regulatory strategy and accelerated pathway engagement Grant-funded translational R&D (SBIR-supported programs) Show More (5) Show less Key Technologies Recombinant protein therapeutics Protein engineering for improved yield and manufacturability Organotypic cultured human lung tissue models In vivo viral infection animal models (SARS‑CoV‑2 mouse models) Nanoparticle-based targeted delivery systems Extracellular-matrix-derived biologic scaffolds P … atment patent NellOne Therapeutics announced the filing of a provisional patent application for the use of the NELL1 signaling protein in treating respiratory viral infections including COVID-19. The patent details methods to reduce tissue damage and inflammation caused by the virus, leveraging NELL1's tissue regeneration properties. NellOne Therapeutics secures key patent to revolutionize large-scale production NellOne Therapeutics received U.S. Patent No. 10,752,663 fo
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Thrilled to welcome Joe Kiani as... - Patient Safety Movement Facebook Log In Patient Safety Movement's Post Patient Safety Movement December 18, 2025 · Shared with Public Thrilled to welcome Joe Kiani as a keynote speaker at our 12th Annual World Patient Safety Summit. His vision and commitment embody what this movement stands for. #ZEROHarm2030 #powertopropelchange #PatientSafety https://psmf.org/.../12th-annual-world-patient-safety.../ All reactions: 3 Like Comment
#rapid #researchtranslation #biotechaustralia #lifesciences #ausbiotech | Gerard Blood | 11 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … cal area where accelerating the journey from scientific discovery to real-world application can significantly improve healthcare outcomes and innovation impact. It’s encouraging to see continued focus on strengthening collaboration between research and industry. You may also find value in this free webinar, The AI Skills Opportunity Across APAC: How Training Providers Can Scale Enterprise AI Workforce Transformation on Jun 11, 2026. It’s a free webinar, and seats are limited—
SMSbiotech - Reg A | Manhattan Street Capital Skip to main content GTranslate English English Chinese Dutch Filipino Finnish German Hebrew Japanese Korean Norwegian Portuguese Spanish Swedish Thai Login Signup Search form Search You are here Home SMSbiotech - Reg A Overview Updates (10) Comments Share Make Reservation Contact Overview Updates (10) Comments Share Make Reservation Contact the future of regenerative healing We are a San Diego-based biotech company that discovered and named the "SMS" human stem cell and are utilizing our patented platform to develop treatments for horrible disease … ies – completed Q4 ’23 Product development – completed Q4 ’23 Compassionate Use application already filed in US/Internationally with focus on COPD patients Current Roadmap of Clinical Trials Ongoing, expected to be completed in Q2 2026 Expected to begin in Q2 2026 and complete in Q1 2027 Expected to begin in Q1 2027 and complete in Q4 2027 The Future - Ramping Up Production We are already producing SMS cells and currently have $8M worth of inventory. This year we are adding t … rovides a powerful proof-of-concept for SMSbiotech’s platform: Broad Veterinary Application: SMS therapy could address complex, hard-to-heal wounds in companion animals—an unmet need in veterinary care. Non-Surgical Regenerative Solution: Potential to reduce reliance on invasive procedures such as amputation or reconstructive surgery. Scalable Translational Value: The mechanism of systemic wound healing has direct implications for human chronic wound and tissue repair markets
AI IN TURNING CHALLENGES INTO OPPORTUNITIES – MOHAMED DIAB – Takreem Foundation Skip to main content Scroll Top Menu Nominate a candidate Ways to support Become a Partner Become a Sponsor Auction My Auctions Orders Addresses Auctions settings Lost password Contact Top Searches: Terms 0 Cart No products in the cart. Menu Home About About Testimonials Boards Laureates Awards Night Events Upcoming Events Fundraising Dinner 2026 – Paris Awards Night 2026 – Riyadh Past Events Shining Stars of Hope 2025 – Beirut Spring Gala Dinner 2025 – Dubai Shining Stars of Hope 2024 – Bei
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Interview with Mohamed Diab: Marvel, DC, and 'Moon Knight' Skip to content About Books Book Reviews Fantasy Funny Books Horror Media Studies Memoirs & Biographical Romance Sci-Fi Audiobooks Book Adaptations Interviews Recommended Reading Comics About Comics Guides Comics Beginners Guide & FAQ Comics Reading Guides Comics Reviews Companion Guides Films & Shows Start Reading Comics Features Guides Comics Reading Guides Companion Guides Gift Guides What to Expect On Location Concert Reviews Cons & Events Exhibits & Experiences Film Festivals Live Shows Travel Rev
Mohamed Diab - CEO at Ebers, Alexandria HOME ABOUT RANKINGS CEO of the Year Performance Excellence Award Corporate Support Award People’s Choice Award All-Time Rankings AWARDS WINNERS RESOURCES Rules and Guidelines Terms of Service EXPLORE News CEOs NOMINATE Login Deutsch Español Dansk Français Italiano Nederlands Norsk Português Suomi Svenska العربية Mohamed Diab Ebers Share this page Copy URL Facebook X Visit Official Site Bio Mohamed Diab is an MBA holder, a tech entrepreneur, and a public speaker in the field of “Biomedical Visualization”, graduated from the faculty of pharmacy
Mohamed Diab: صاحب بالين ... | TED Talk Ideas change everything WATCH TED Talks Browse the library of TED talks and speakers Playlists 100+ collections of TED Talks, for curious minds TED Series Go deeper into fascinating topics with original video series from TED TED-Ed videos Watch, share and create lessons with TED-Ed TEDx Talks Talks from independently organized local events TED Fluent Watch TED Talks in your language DISCOVER Topics Explore TED offerings by topic Podcasts Explore the TED Audio Collective Ideas Blog Our daily coverage of the world of ideas Newsletters Inspiration delivered … pand on their world-changing ideas PARTICIPATE Nominate Recommend speakers, TED Prize recipients, Fellows and more Organize a local TEDx Event Rules and resources to help you plan a local TEDx event TED-Ed Award-winning educational content and programs Translate Bring TED to the non-English speaking world TED Fellows Join or support innovators from around the globe ABOUT Our Organization Our mission, history, team, and more Conferences TED Conferences, past, present, and futu
Join us in welcoming Mohamed Diab,... - Narrative Summit Facebook Log In Narrative Summit's Post Narrative Summit October 5, 2023 · Shared with Public Join us in welcoming Mohamed Diab, Egyptian Filmmaker and Director of Marvel Studio's MOON KNIGHT as a creative speaker at the Narrative PR Summit on October 9th, 2023 at Somabay. Diab is the director of Marvel’s live-action series, MOON KNIGHT starring Oscar Isaac, Ethan Hawke, and May Calamawy. #narrativepraummitspeakers #narrativeprsummit2023 #october9th #thestorytellersareback #egyptforeverforward +6 All reactions: 107 1 comment 3
Mohamed Diab - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Career Toggle Career subsection 1.1 Cairo 678 1.2 Eshtebak (Clash) 1.3 Moon Knight 2 Filmography Toggle Filmography subsection 2.1 Feature films 2.1.1 Only writer 2.2 Television 3 Awards Toggle Awards subsec … mic in Cairo. The film was released in December 2010 and is considered the most award-winning contemporary Egyptian film. The film was distributed internationally and fared well notably in France, where it sold 265,000 tickets and received ÉcranTotal's "coup de foudre du public" audience recognition award. [ 3 ] Eshtebak (Clash) [ edit ] Eshtebak (Clash) was supposed to be a film about the rise of the Egyptian revolution but eventually became a film that captures the … nal Film Festival Best Actor Best Actress Asia Pacific Screen Awards Jury Grand Prize High Commendation Sydney Film Festival Special Mention Montpellier Mediterranean Film Festival Prix Du Public Prix Jeune Public Taormina Film Festival Youth Choice Award Heartland Film Festival Grand Prize Khouribga African Film Festival Best Film Best Supporting Actress Third Eye Asian Film Festival Best Film Mediterranean Film Festival Best Film Salé Women's Film Festival Special Mention A … Film Festival Special Mention African Film Festival of Cordoba Audience Choice Award Cologne African Film Festival Audience Choice Award Egyptian Oscars Best New Director Egyptian Catholic Center for Cinema Festival Jury Prize Arabian Sights Film Festival Audience Choice Award In 2011, Christiane Amanpour presented Mohamed Diab with a Webby Award. [ 8 ] References [ edit ] ^ "6 معلومات عن محمد دياب العضو المصرى بلجنة تحكيم "Un Certain Regard" " . Youm7 . Retrieved 15 … tober 2020). " 'Moon Knight': Mohamed Diab To Direct Marvel's Disney+ Series" . Deadline Hollywood . Retrieved 27 October 2020 . ^ "How 'Moon Knight' Harnessed the Power of Egypt's Top Creatives — and Even Flew Over a Taxi Driver — to Push for Authenticity and "Avoid the Orientalist Look" " , hollywoodreporter.com , 6 April 2022 ^ "Egyptians Take
Mohamed Diab – New York Film Academy Alumni Quick Links For Current Students Parents *UPCOMING ONLINE INFO SESSIONS* 1-800-611-FILM Search English Russian Spanish Arabic Italian Portuguese Japanese Korean Mandarin Search Academics AREAS OF STUDY Filmmaking Acting for Film Photography Producing Screenwriting Cinematography Documentary Filmmaking Digital Editing 3D Animation & Visual Effects Broadcast Journalism Musical Theatre Game Design Entertainment Media Cinematic AI NYFA's Pathway Track DEGREE PROGRAMS Bachelor of Fine Arts Master of Fine Arts Master of Arts Associate of Fine Arts Onli … dy Exchange Programs (FASE) Admissions & Finances ADMISSIONS Program Dates Application Deadlines Admissions Requirements International Students Veterans & Military Dependent Students Transfer Students Cross-Campus Studies Advanced Standing and Tuition Credit Meet NYFA Near You Health Requirements FINANCES Tuition Federal Financial Aid SCHOLARSHIPS & GRANTS GI Bill & Yellow Ribbon Program MAKE A PAYMENT Housing Information Open House & Live Online Events E … York City Los Angeles Florence, Italy Cambridge, MA Paris, France Request Info Apply Now NYFA / ALUMNI / SCREENWRITING / MOHAMED DIAB Mohamed Diab DIRECTOR | SCREENWRITER Graduated from NYFA LA Campus in 2005 Mohamed Diab is an Egyptian screenwriter and filmmaker who made history as the first Arab director tapped by Marvel, leading four episodes (and executive producing) Moon Knight on Disney+. Early in his career he penned successful Egyptian films such as Real Dreams, The … . Today, he is the lead director and executive producer of Marvel Studios’ Emmy Award-winning series Moon Knight, available to… Twelve New York Film Academy Alumni at the 2021 Red Sea Film Festival Twelve New York Film Academy (NYFA) filmmaking, acting, screenwriting, and short-term workshop alumni have works that were selected for Saudi Arabia’s Red Sea Film Festival. This festival marks the first big… NEW YORK FILM ACADEMY (NYFA) SCREENWRITING ALU … -year screenwriting program in 2005. The Egyptian filmmaker… Request Info Apply Now Visit us NYFA Brochures Store Faculty Alum network JOBS Teach-Out Policy RU ES AR IT PT JP KR CN Copyright © 2026 New York Film Academy • Privacy Policy All programs and workshops are solely owned and operated by the New York Film Academy and are not affilia
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
BioLeonhardt | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies BioLeonhardt BioLeonhardt is dedicated to advancing regenerative medicine, particularly in heart regeneration, through innovative bioelectric stimulation devices and stem cell therapies. Their mission is to develop reliable, organ-regenerating solutions that leverage patented micro stimulation and micro pump technologies, aiming for complete organ regeneration and improved patient outcomes. Industries biotechnology electronics health-care Nr. of Employees small (1
Keynote w/ Joe Kiani, the Founder, Chairman, CEO of Willow Labs, and Founder of Masimo | LSI USA '25 | Joe Kiani LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si
Joe Kiani - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
350. LSI Keynote: Masimo Founder Joe Kiani on beating Apple and lessons learned on the path to building a billion dollar company - State of Medtech | Podcast on Spotify
Masimo’s Founder and CEO Joe Kiani On CHOC Board - CHOC Inside Skip to primary navigation Skip to main content Skip to footer You are here: CHOC Inside Home » CHOC Inside » Healthcare » Masimo’s Founder and CEO Joe Kiani On CHOC Board CHOC Home CHOC Inside News and stories about Children's Health of Orange County About CHOC Donate Careers Press room For parents For medical professionals CHOC.org Search this website Subscribe Children's Hospital of Orange County is now part of Rady Children's Health . Masimo’s Founder and CEO Joe Kiani On CHOC Board Link: https://inside.choc.org/masimos-fo … numerous awards, including the Newborn Foundation Hubert Humphrey Dawn of Life Award, the Ibero-American Society of Neonatology (SIBEN) Award for Improvement of Neonatal Health in Latin America, and the City of Hope Humanitarian Award. “I have had the privilege to see firsthand the dedication of the staff at CHOC, from their CEO to their doctors and nurses,” said Joe Kiani . “I am delighted to serve CHOC as they continue to provide the best care for our children and ad
Joe Kiani | Keynote Speaker | AAE Speakers Bureau 1.855.383.8805 Contact Us Speakers Topics Business Strategy Cybersecurity Diversity and Inclusion Education FinTech Future of Work History Leadership Mental Health Motivational Politics Social Activism Sports STEM Sustainability and Climate Change Work Life Balance >> View All Topics Resources About Contact Us 1.855.383.8805 Home Speakers Joe Kiani Joe Kiani Keynote Speaker: Founder, Chairman & CEO of Masimo, a Medical Technology Company Travels From: Orange County, CA, USA Speaking Fee: Live Event Fee: $100,000 - $200,000 Virtual Eve … policy. In 2012, he won the Ernst & Young National Entrepreneur of the Year award in life sciences. He is also responsible for creating the Patient Safety, Science & Technology Summit. Contact a speaker booking agent to check availability on Joe Kiani and other top speakers and celebrities. BOOK JOE KIANI FAQs on booking Joe Kiani How do I book Joe Kiani to speak at my event? Our experienced booking agents have successfully helped clients around the world secure speak … rtually any speaker or celebrity in the world. Our agents are happy and able to submit an offer to the speaker or celebrity of your choice, letting you benefit from our reputation and long-standing relationships in the industry. Please click the Check Schedule button above and complete the form on this page including the details of your event, or call our office at 1.855.383.8805 , and one of our agents will assist you to book Joe Kiani for your next private or corporate func … rtually any speaker or celebrity in the world. Our agents are happy and able to submit an offer to the speaker or celebrity of your choice, letting you benefit from our reputation and long-standing relationships in the industry. Please click the Check Schedule button above and complete the form on this page including the details of your event, or call our office at 1.855.383.8805 , and one of our agents will assist you to book Joe Kiani for your next private or corporate func … ; Member of the Forbes Technology Council on AI View Profile Dr. Joel Selanikio Award-Winning Physician & Futurist Working at the Intersection of Technology & Healthcare; Former CDC Epidemiologist View Profile Eric Lefkofsky AI and Precision Medicine Leader; Tech Entrepreneur and Investor View Profile Zack Kass Global AI Advisor and Forme
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
SMSbiotech Advances Lung Regeneration at RIS | Abdulkader Rahmo posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Li … a diagnostics — and exciting to work on ongoing research exploring the clinical application of plasma pTau217 in a secondary setting🩸 Kristian Steen Frederiksen Professor of Neurology - University of Copenhagen Director of the Clinical Trial Unit - Danish Dementia Research Centre 1mo Very happy that we at the Clinical Trial Unit at Danish Dementia Research Centre ( Nationalt Videnscenter for Demens ) were able to contribute to Roche Diagnostics APPROACH study to assess the c … kd.in/efxQZPAK In my group we are continuing to explore the real-world clinical application of pTau217 in plasma (using the Elecsys platform) in a study led by PhD-sudent Helena Sophia Gleerup . In the study we are testing whether its use as a triaging test in a secondary setting will lead to a reduced need for ancillary investigations and a shorter time until diagnosis while maintaining the same diagnostic accuracy. 12 Like Comment Share Copy LinkedIn Facebook X To view or a
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Learning Center | Globalator Build-to-Sell Services Powered by TBGM Learning Center Learning Center Build-to-Sell Learning Center We have put together a number of resources for business owners and business decision makers that would like to explore whether a Build-to-Sell process is for them. No matter if you choose to work with Globalator or do it yourself, we believe you will find these resources valuable. Live Case Study Webinar HTB-Forum “Build-to-Sell” The following list provides access to recordings from past High-Growth Technology Business Forum (HTB-For
2023 Cardiac Physiome Workshop | Cardiac Physiome Society Log In Search Skip to content Cardiac Physiome Society The website of the Cardiac Physiome Society Menu Home Meetings 2013 Cardiac Physiome Workshop Attendees Program Registration Abstracts & Posters Travel Information Contact 2015 Cardiac Physiome Workshop Abstracts and Posters Attendees Keynote Speakers Location Program Registration Satellite meetings Travel and Accommodation 2016 Cardiac Physiome Workshop Abstracts and Posters Accomodation, Travel, and Sightseeing Attendees Keynote Speakers Programs Registration 2017 Cardiac Phy
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Details about Administration Deanships Publications & Presentations Policies and Procedures admissions Admission Office Apply to PMU Financial Aid Registration academics Engineering Computer Engineering & Sciences Business Administration Sciences & Human Studies Prep Core LAW research Students Life Campus Life Health Care & Counseling Services Office of Special Needs signin Campus Life Health Care & Counseling Services Office of Special Needs × Other Services Login Please fill in below form to create an account with us Banner Banner BlackBoard Oracle Self Service Direct Link Back To Logi
Speakers | 20th Annual International Vein Congress No notifications yet. Sign Out Toggle navigation More Registered User? Login Forgot Password? Sign Up New User? Sign Up Forgot Password? Login Our Speakers A D Dr. Alan Dietzek Vascular Surgeon Nuvance Health C P Constantino Pena MD C S Cynthia Shortell MD E M Dr. Edward G. Mackay MD, FACS, RPVI, RVT F L Dr. Fedor Lurie Research Director Jobst Vascular Institute G K Ghassan Kassab PHD J S Jan Sloves RVT, RCS, FASE J A Mr. Jose I. Almeida MD, FACS, RPVI, RVT J J Julian Javier MD, FSCAI, FCCP K H Kandy Hammond RN, BSN, MBA/HCM K G Kathleen Gibso
%PDF-1.7 %���� 1 0 obj >/Metadata 185 0 R/ViewerPreferences 186 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.56 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��\Yo�H~7�����\�m�E6� ��8��ɮ��b��#1�[�JTf����%Fjy�D��U]�WGw��d^M���*x�������_������ݬ8�̯'Ӽ����� /}(�Q1�&8}{��� f1�gL��8Йf: �,V��8 �È� ���W���m� � ▘ܝ����Yp�P�iYU�['�ʲ�V'"0�Ir���5���H��H��H�%�;�O� >S�ё/�)�Rᯂn��� �, �]� ��O��:����W�v�� �Du s�� ���;�;���D��4 Re7� ��1�'�W�P �[|}��d8� }���u���q7��=��X� �q�s��
%PDF-1.3 %���� 35 0 obj > endobj xref 35 44 0000000016 00000 n 0000001499 00000 n 0000001579 00000 n 0000001758 00000 n 0000002017 00000 n 0000002083 00000 n 0000002184 00000 n 0000002283 00000 n 0000007056 00000 n 0000011554 00000 n 0000015970 00000 n 0000020560 00000 n 0000024996 00000 n 0000029321 00000 n 0000029764 00000 n 0000030315 00000 n 0000031014 00000 n 0000031390 00000 n 0000031765 00000 n 0000032138 00000 n 0000032499 00000 n 0000032914 00000 n 0000033381 00000 n 0000033676 00000 n 0000033942 00000 n 0000038352 00000 n 0000043075 00000 n 0000043916 00000 n 0000047210 00000 n 00000 … Z$��������d�'Z��{�-o���XU�ѕ��}����;�E�f9��$N$�� > endobj 72 0 obj >stream application/postscript Adobe Illustrator CS2 2006-11-20T08:35:18-05:00 2006-11-20T08:35:18-05:00 2006-11-20T08:35:18-05:00 232 256 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fH … Z$��������d�'Z��{�-o���XU�ѕ��}����;�E�f9��$N$�� > endobj 76 0 obj >stream application/postscript Adobe Illustrator CS2 2006-11-20T08:35:18-05:00 2006-11-20T08:35:18-05:00 2006-11-20T08:35:18-05:00 232 256 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fH … Z$��������d�'Z��{�-o���XU�ѕ��}����;�E�f9��$N$�� > endobj 10 0 obj >stream application/postscript Adobe Illustrator CS2 2006-11-20T08:35:18-05:00 2006-11-20T08:35:18-05:00 2006-11-20T08:35:18-05:00 232 256 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fH … ess: pictwpstops filter 1.0 2007-10-02T12:43:33-04:00 2007-10-02T14:28:26-04:00 application/pdf Administrator 20183_BMENewsletter.qxd uuid:a2c0d42c-7106-11dc-95d0-0017f20968b6 uuid:8cd9c004-f891-44ce-aef4-e00a42e78788 endstream endobj 34 0 obj > endobj xref 0 35 0000000000 65535 f 0000171283 00000 n 0000171409 00000 n 0000171670 00000 n 000019166
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.7 %���� 1427 0 obj > endobj 1449 0 obj >/Filter/FlateDecode/ID[ ]/Index[1427 302 1733 1]/Info 1426 0 R/Length 121/Prev 16818816/Root 1428 0 R/Size 1734/Type/XRef/W[1 2 1]>>stream h�bbd``b���F@��H�� �bW H�,̍ ��5DȂ�� H �o Q�H\l� ك@BDnJ ��&FV} ���q�A���0iħ�8 p�����L��01�_ endstream endobj startxref 0 %%EOF 1728 0 obj >stream h�b```b`0``c`�ac@1�( ��`�JP�,̟�j%��ȡ���p�E����30)H_p;.��ӽB��%��� �� �� 2�\,$970�;�d0�2h�AF[�| �Y9��ʪ̋��>���0��$Ǣo!�^ Z���/Ѝ4���p6T� ��gᵇ�x�Y* $nerLv��az+�5Y�o������ʮU]�V�mKq�>����s�̙iii`g3�(�l5��h &b:�: 4ҭ�BL4�-����k�@��qd�_� … M%��I�k�{��q_i�G� 5)_��!Y[x�sf���� lY� ��������z]K�cP�U���o����?���5�����RfP Y4r�A�4N���``V�����g �r�7�W��,� �#��|��9E���ܬ�L��1��n'��ˤ�Q:B�`2��0��L&� 2��F�9 � SP& �� eq2 �)(���,����2�3�0�Yt&F02� �"�r� �3Q&��' ���ߜ:r�����N��?|��YP N &d��IJₒ��?����6oܸ}���yk��5kv�����_m�� e��م�a�SG��*UV�5l� ���'��g�h�Iܺo�g�)�PQ~l �Rl���?=��� �y������x�G���=��OO����7�.\���}�yw��� ��ۼG��:՝Ή6��3d���{�&Z ���yЫ�q�����~M�I֠뫵�[�^0h j��6�U 5k�El�a��ux�> … ׄ �,V�QE�y�#N��^�?�:آ�(���/�)|9?�� �L ������߰�֮� ^���X����\���O=�r8e�G@RFp@ ���wNK=�&��6%�e�ey73K�Ns�����]���8:mĶ���l�� �ح��ٞ�{Ԗzd�L�F�4��F�7 &�.�`D��i� �� �CZ�����줶�[ ���60"��UC4� ���Nj ���x�M��n�^�f�)"PS{��C~\d ������wo.��v��k�tF� RVP � �.�ui�4l,����]�*�͈3� ����.��j/$:��a'�5o�[��F0��v:�c#�zQ�i����R�>�$���P*Ƞo#��~�o|o,��,�i�#��6� ���Fd$ ��++J�P�� d�AU(�o��'���w��l�u��}-!���wlft*�# s�H8=�k^�;��|=k �sbt�4�*�EX� hA��H��j��o�M��cL�J����x��@# … 2.85.2 2023-07-31T09:07:46-07:00 2023-07-31T09:07:46-07:00 Bluebeam Brewery 5.0 application/pdf uuid:16eabc0e-82ec-439e-a011-83ac14841437 uuid:3a21a0f6-87a1-4272-b4a1-7e7d6457dee0 endstream endobj 344 0 obj >stream h��Zێ9������� �d.���$A:�����x���� �{��� �H�eUE�.�X�C�(�tD �*�'���R a���� AHCJ� yH��$ �q��K�̺���ɦ���.'8;�n �@�� �1W���8ѕ��U� � H8��\����}�zv�A7�Z�� �����v{��i���������ի�������Y�ן �������i����� ���� (b��g�� u��#q ��M(&� b¨A����=�ߣ� ]�ge�!�h�K5�Ġ … T09:19:46-07:00 2023-07-31T09:19:46-07:00 Adobe Acrobat Pro (32-bit) 23.3.20244 application/pdf Rios, Hector uuid:726b864e-9e24-45da-af66-8945769b7fad uuid:78b6fcf9-669e-4aba-9001-59180f614f15 editedScannedDoc 2023-07-31T09:19:47-07:00 Page:21 Adobe Acrobat Pro (32-bit) 23.3.20244 endstream endobj 351 0 obj >stream hޜ��j1 �_Eop�lY6�, ��Эd�(]��$
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
American Thoracic Society | Respiratory Innovation Summit Skip to content ATS Conference Logo Thoracic.org Journals ATSNOW ATS Ed+ About Press Conference History Code of Conduct About arrow_forward Program ATSConference365 launch Early Career Professionals BEAR Cage Fellows Track Symposium New Faculty Boot Camp Resident Boot Camp Student Scholars Program Respiratory Innovation Summit Continuing Medical Education (CME) Maintenance of Certification (MOC) Past Program Itineraries Program arrow_forward Attend Certificate of Attendance launch Membership ATS Member Community Code of Conduct Future C … All companies innovating in pulmonary, critical care or sleep are encouraged to apply. All applications will be reviewed. The 2026 event featured 80 companies, 36 of which were selected for oral presentation. The agenda also includes venture capital panel, business development panel, and plenty of time for networking. For questions or to learn more, please email Dustin Bell at [email protected] . Dates: Friday, May 14 & Saturday, May 15, 2027 Apply to be Featured Learn M
SMSbiotech Science | Small Mobile Stem Cells & Regenerative Medicine Wait, before you go! Subscribe to get important updates and helpful insights delivered straight to your inbox. Thank you! We received your submission! Oops! Something went wrong Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about … r and more robust, providing practical benefits in their handling, storage, and application. Subscribe for updates Thank you! We received your submission! Oops! Something went wrong Science The Science Animal Studies Human Studies News & Updates Company About Us Leadership Careers Pipeline Overview Contact Us Contact Terms & Conditions of Sales Terms of Use © 2026 SMSbiotech All rights reserved. The information regarding the investigational product is for educational
SMSbiotech Advances Cell Therapy at Advanced Therapies Week 2026 | SMSbiotech posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y … t-based research with a focus on scalability, immune modulation, and real-world application. We believe this approach represents a significant opportunity in the evolution of cell therapy. $FBLG #Biotech #CellTherapy #LifeSciences #HealthcareInnovation …more Why Fibroblasts Matter More Than You Think 15 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Peter Sommer, PhD 3mo Report this post Unlocking the Promise of iPS Cells: A Major Leap
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Abdulkader Rahmo - COPD Drug Development Summit Skip to content AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012) Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches September 15-17, 2026 | Boston, MA About About Event Poster Session FAQs Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Pre-Conference Day Day One Day Two Why Par
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Abdulkader Rahmo, SMSbiotech --> --> --> --> Featured by Newsweek & World Class Media Outlets Reports Events Interviews Careers About Search --> Home Interviews Abdulkader Rahmo Abdulkader Rahmo Co-Founder, President & CEO SMSbiotech 09 April 2025 Share Interview SMSbiotech is a biotech company based in California, specializing in regenerative medicine through the discovery and development of a novel human stem cell known as the Small Mobile Stem (SMS) cell. 2025 is a pivotal year for SMSbiotech… Absolutely! We have received approval to move forward with our Phase 1 clinical trial in
Presented SMS cell therapy at Respiratory Innovation Summit | Abdulkader Rahmo posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Home - Sciinov Conference Overview About Become a Speaker Sponsor/Exhibit Organizer Info Speakers Speakers 2027-singapore Speakers 2026 Japan Speakers 2026 Dubai Speakers 2025 Edition 2 Speakers 2025 Speakers 2024 Edition 2 Speakers 2024 Speakers 2023 Speakers 2022 Speakers 2021 Speakers Q4 2020 Virtual Speakers Q3 2020 Virtual Speakers 2019 Program Scientific Sessions Scientific Program Brochure Download Partners Information Important Dates Venue Guidelines Publication Pricing / Registration Quick Downloads News Reports Past Events Submit Abstract Help & Support Registration Overview Abou … nes Publication Pricing / Registration Quick Downloads News Reports Past Events Submit Abstract Help & Support Registration Featured Speakers HOME Featured Speakers Abdulkader Rahmo SMSbiotech, USA None Small Mobile Stem Cells Potential for Rejuvenating Tissue Parenchyma in Ageing Individuals Co-Founder, President, CSO of SMSbiotech Bachelor in biochemistry from the Swiss Federal Institute of Technology (ETH) in Zurich; Ph.D. in Biochemistry from the University of Souther
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Dr. Rahmo Showcases SMSbiotech’s Breakthrough Cell Therapy at Biotech Global Summit. | SMSBiotech Blog Our Team Technology Science Explore our proprietary Small Mobile Stem (SMS) cell technology Animal Studies Review our pre-clinical proof-of-concept and safety studies Human Studies Track our groundbreaking Phase I clinical trial targeting COPD. News & Updates Discover our latest breakthroughs, company news, and milestones About us Learn about our mission to revolutionize regenerative medicine Leadership Meet the team of leading researchers, business executives, and expert advisors Careers … , and potent “off-the-shelf” (allogeneic) therapies designed for broad clinical application. This platform is currently being evaluated in a Phase 1 clinical trial for Chronic Obstructive Pulmonary Disease (COPD) —a debilitating condition with no known cure. We are honored to share this milestone with the global health community and remain deeply grateful for your continued support. Resources No items found. Published on: 26 Oct 2025 Copy link This is some text inside o … ticle 10th International Conference on COPD and Lung Health Next Article Patent Application Accepted Next Article 6th Annual IPF Summit 2022 Next Article 4th Annual Longevity Therapeutics Summit Next Article Voice of America - Innovations Next Article SMSbiotech Receives New Patent!!! Next Article ISSCR 2022 Poster Presentation Next Article Scientific Poster from ATS: Respiratory Innovation Summit 2022 Next Article ATS: Respiratory Innovation Summit 2022 Next Article Medicina … tech Next Article ACS National Meeting & Expo Next Article SMSbiotech Files Proposal with BARDA for a Covid-19 Treatment Next Article SAWC Spring | WHS Next Article Advanced Therapies Congress & Expo 2020 Next Article Joe Kiani Becomes A Major Shareholder At SMSbiotech, Inc. Next Article SMSbiotech Introduces a New Product Website! Next Article ANGIOstream™ In Vitro Assay Fast Track Option – Inductive Niche Module (INM) Next Article Biotechnology Vendor Showcase™ – So
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
SMSbiotech Initiates Groundbreaking Phase 1 Human Clinical Trial for COPD Submit a Release Home All ESG Health Technology Finance Contributors Sub Menu Submit a Release main-search-pop Main menu SMSbiotech Initiates Groundbreaking Phase 1 Human Clinical Trial for COPD Contributed by: Business Wire Logo Images Dr. Abdulkader Rahmo Tags Science Stem Cells Biotechnology Research Pharmaceutical Health Clinical Trials Other Health SMSbiotech More Like This SMSbiotech Establishes a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Chemical Defense Brenus … e All ESG Health Technology Finance Contributors Press Release Hub Our Services Submit a Release Websites PA Media Group PA Mediapoint Distribution Packages © PA Media Group. 2026 Terms of Use Privacy Policy Contact Us
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ